Estimated effectiveness was 65% against hospitalization, 74% against pediatric intensive care unit admission, and 64% against ...

A study from Yale University today in JAMA Network Open reveals substantial protection by the preventive drug nirsevimab ...

Getting vaccinated during pregnancy protects your newborn from severe infection during the first critical months of life.

with FDA approval of Beyfortus for the prevention of RSV disease in infants. The US regulator has cleared the one-shot monoclonal antibody to prevent RSV lower respiratory tract disease in ...

Currently, nirsevimab (Beyfortus) is recommended as an option ... whereas nirsevimab targets site Ø. Another monoclonal ...

vaccine for pregnant individuals and the monoclonal antibody nirsevimab (Beyfortus) for newborns—has shown high uptake in a recent cohort study. 1 Conducted at a single academic center ...

Some market observers point to stronger efficacy data with Beyfortus than Pfizer’s shot, particularly on severe disease, as well as clinician familiarity with use of antibodies. That could drive ...

Nirsevimab, trade name Beyfortus, is unlikely to be fully ... manufacturer Sanofi said in late October. Nirsevimab is a monoclonal antibody that protects infants and toddlers against severe ...

The pioneering beyfortus provides a solution to decrease RSV cases. It bolsters passive immunity through a single-dose monoclonal antibody, nirsevimab, which targets and neutralizes the ...

Beyfortus has emerged as a groundbreaking solution for RSV prevention. The single-dose monoclonal antibody nirsevimab enhances passive immunity by neutralizing RSV, significantly reducing the risk ...